The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) reached all time high today, Nov, 18 and still has $32.39 target or 52.00% above today’s $21.31 share price. This indicates more upside for the $995.55M company. This technical setup was reported by Barchart.com. If the $32.39 PT is reached, the company will be worth $517.69M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 37,205 shares traded hands. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 66.41% since April 18, 2016 and is uptrending. It has outperformed by 61.98% the S&P500.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Ratings Coverage
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Amphastar Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The rating was upgraded by Zacks to “Hold” on Tuesday, August 18. Zacks downgraded the stock to “Buy” rating in Monday, August 10 report. BMO Capital Markets initiated the shares of AMPH in a report on Wednesday, June 29 with “Market Perform” rating. The firm has “Buy” rating by Jefferies given on Tuesday, August 9. Jefferies maintained Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Tuesday, January 19 with “Buy” rating. As per Friday, February 19, the company rating was initiated by Wells Fargo. The firm has “Buy” rating given on Tuesday, May 10 by Needham.
According to Zacks Investment Research, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.”
Insitutional Activity: The institutional sentiment increased to 3.17 in 2016 Q2. Its up 1.07, from 2.1 in 2016Q1. The ratio is positive, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Walleye Trading Limited reported 300 shares or 0% of all its holdings. State Bank Of Mellon reported 190,849 shares or 0% of all its holdings. The Ohio-based Strs Ohio has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Alliancebernstein Limited Partnership has 105,630 shares for 0% of their US portfolio. Kalmar Investments De accumulated 210,715 shares or 0.15% of the stock. City Hldg has 0% invested in the company for 400 shares. Ubs Asset Management Americas accumulated 205,975 shares or 0% of the stock. Proshare Advsrs Ltd Liability Corporation reported 37,737 shares or 0.01% of all its holdings. Schwab Charles Mngmt Incorporated has 72,893 shares for 0% of their US portfolio. Bogle Lp De last reported 0.13% of its portfolio in the stock. Fisher Asset Ltd Liability, a Washington-based fund reported 250,331 shares. Savings Bank Of Montreal Can last reported 0% of its portfolio in the stock. Blackrock owns 2,276 shares or 0% of their US portfolio. Oberweis Asset has 0.13% invested in the company for 27,200 shares. Deere Company holds 20,260 shares or 0.02% of its portfolio.
Another recent and important Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) news was published by Fool.com which published an article titled: “Why Amphastar Pharmaceuticals, Inc. is Soaring Today” on September 20, 2016.
AMPH Company Profile
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment makes, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment makes and distributes recombinant human insulin and porcine insulin. The Firm makes and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.